ReviewUrologie (Heidelberg, Germany)2026
[New guideline for supportive care-what is relevant for urologists?]
Review in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The updated S3 guideline for supportive care (version 2.0, as of April 2025) provides an evidence-based, interdisciplinary framework for the supportive management of oncology patients. Supportive care encompasses measures aimed at preventing and managing therapy-induced side effects, with the goal of maintaining quality of life, avoiding therapy discontinuation, and ensuring holistic patient care. The new version expands the previous ten topic areas with four central focuses: management of side effects from immunotherapies, cardiovascular complications, central neurotoxicity, and radiation-induced side effects in the genitourinary tract. The guideline offers concrete recommendations for monitoring, prevention, and management of side effects associated with modern therapies, emphasizing the importance of patient-centered and interdisciplinary care. For urologists, the explicit discussion of radiation-induced side effects in the genitourinary tract is particularly relevant, including incontinence, bladder emptying disorders, and sexual dysfunction. The guideline supports structured long-term follow-up, enhances interdisciplinary collaboration, and enables evidence-based planning and management of side effects. Despite comprehensive evidence, the effectiveness of the guideline critically depends on consistent implementation, sufficient resources, and individualized adaptation to patients. The S3 guideline 2025 thus provides a foundation for optimized supportive care in urologic oncology and promotes sustainable improvement of function and quality of life for patients.
Indexed as
Identifiers
41912883What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.